Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
- PMID: 27569438
- DOI: 10.1161/CIRCULATIONAHA.116.022802
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
Abstract
Background: Atrial fibrillation is associated with increased but variable risk of stroke. Our aim was to validate the recently developed biomarker-based ABC (age, biomarkers [high-sensitivity troponin and N-terminal fragment B-type natriuretic peptide], and clinical history of prior stroke/transient ischemic attack)-stroke risk score and compare its performance with the CHA2DS2VASc and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) risk scores.
Methods: The ABC-stroke score includes age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac troponin), and clinical history (prior stroke). This validation was based on 8356 patients, 16 137 person-years of follow-up, and 219 adjudicated stroke or systemic embolic events in anticoagulated patients with atrial fibrillation in the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy). Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardiac troponin I (hs-cTnI) were determined in plasma samples obtained at study entry.
Results: The ABC-stroke score was well calibrated with 0.76 stroke/systemic embolic events per 100 person-years in the predefined low (<1%/y) risk group, 1.48 in the medium (1%-2%/y) risk group, and 2.60 in the high (>2%/y) risk group for the ABC-stroke score with hs-cTnT. Hazard ratios for stroke/systemic embolic events were 1.95 for medium- versus low-risk groups, and 3.44 for high- versus low-risk groups. ABC-stroke score achieved C indices of 0.65 with both hs-cTnT and hs-cTnI, in comparison with 0.60 for CHA2DS2VASc (P=0.004 for hs-cTnT and P=0.022 hs-cTnI) and 0.61 for ATRIA scores (P=0.005 hs-cTnT and P=0.034 for hs-cTnI).
Conclusions: The biomarker-based ABC-stroke score was well calibrated and consistently performed better than both the CHA2DS2VASc and ATRIA stroke scores. The ABC score should be considered an improved decision support tool in the care of patients with atrial fibrillation.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifiers: ARISTOTLE, NCT00412984; RE-LY, NCT00262600.
Keywords: anticoagulation; atrial fibrillation; models, cardiovascular; prevention and control; risk assessment; stroke.
© 2016 American Heart Association, Inc.
Comment in
-
Atrial fibrillation: New score for stroke risk.Nat Rev Cardiol. 2016 Nov;13(11):634-635. doi: 10.1038/nrcardio.2016.156. Epub 2016 Sep 15. Nat Rev Cardiol. 2016. PMID: 27629514 No abstract available.
Similar articles
-
Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time.J Am Heart Assoc. 2017 Jun 23;6(6):e004851. doi: 10.1161/JAHA.116.004851. J Am Heart Assoc. 2017. PMID: 28645934 Free PMC article. Clinical Trial.
-
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4. Lancet. 2016. PMID: 27056738 Clinical Trial.
-
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.Circulation. 2019 Feb 5;139(6):760-771. doi: 10.1161/CIRCULATIONAHA.118.038312. Circulation. 2019. PMID: 30586727 Free PMC article. Clinical Trial.
-
Clinical Applications of Biomarkers in Atrial Fibrillation.Am J Med. 2017 Dec;130(12):1351-1357. doi: 10.1016/j.amjmed.2017.08.003. Epub 2017 Aug 16. Am J Med. 2017. PMID: 28822701 Review.
-
Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation.Cardiovasc Hematol Disord Drug Targets. 2017;17(1):58-63. doi: 10.2174/1871529X17666170104120746. Cardiovasc Hematol Disord Drug Targets. 2017. PMID: 28056733 Review.
Cited by
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584. Eur Heart J. 2018. PMID: 29069359 Free PMC article. Clinical Trial.
-
Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detection.Sci Rep. 2021 Jan 28;11(1):2525. doi: 10.1038/s41598-021-81965-3. Sci Rep. 2021. PMID: 33510263 Free PMC article.
-
The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention.Handb Clin Neurol. 2021;177:345-357. doi: 10.1016/B978-0-12-819814-8.00021-4. Handb Clin Neurol. 2021. PMID: 33632452 Free PMC article.
-
Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation.Europace. 2023 Jul 4;25(7):euad200. doi: 10.1093/europace/euad200. Europace. 2023. PMID: 37461214 Free PMC article.
-
Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.PLoS Med. 2021 Feb 3;18(2):e1003405. doi: 10.1371/journal.pmed.1003405. eCollection 2021 Feb. PLoS Med. 2021. PMID: 33534825 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials